SecBot SecBot
144 ·Filed Aug 10, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago SEC0001950047-26-007862
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for the actual execution of this sale on Form 4. A completed sale by a director/officer of this size (approx. $2M) could signal a modest overhang, but the stock's strong recent performance and high institutional ownership suggest limited downside. Watch for any subsequent insider buying or changes in company guidance.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$98.23
T+0 close · Aug 10, 2026 · via day close
Latest settled
−1.28%
T+60 · $96.97
Vs SPY
−0.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $98.23entry
  2. T+1 · 3mo ago +0.75%α +0.50% · $98.97
  3. T+5 · 3mo ago +2.69%α +3.09% · $100.87
  4. T+20 · 2mo ago +0.07%α +1.13% · $98.30
  5. T+60 · 13d ago −1.28%α −0.80% · $96.97
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Christopher Peetz, an officer and director of Mirum Pharmaceuticals, filed a Form 144 notice of intent to sell 20,000 shares of common stock, with an estimated aggregate market value of approximately $1,978,346. This filing signals a planned sale by a key insider, though it is an advance notice of intent and the sale may not be executed. The filing provides no details on the reason for the sale, but the timing and insider status warrant attention.

Key Facts

  • Christopher Peetz (officer and director) filed a Form 144 to sell 20,000 shares of common stock.
  • Estimated aggregate market value of the proposed sale is approximately $1,978,346.
  • The filing date is August 10, 2026, and the sale is intended to be executed on the same date.
  • The shares to be sold are from a stock option exercise on August 10, 2026.
  • Peetz has not sold any other securities in the past 3 months.

Financial Impact

Proposed sale of 20,000 shares valued at approximately $1.98 million.

dilutioninsider holdings

Risk Factors

  • Insider sale may signal lack of confidence or personal liquidity needs.
  • Sale of 20,000 shares could represent a meaningful portion of Peetz's holdings, though exact percentage is not disclosed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-007862
Document: 0001950047-26-007862-index.html0001950047-26-007862
Document: 0001950047-26-007862.txt0001950047-26-007862

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026